Department of Artificial Intelligence, Nanjing University of Information Science and Technology (NUIST), Nanjing 210044, China.
Menzies School of Health Research, Darwin 0810, Australia.
Genes (Basel). 2022 Mar 5;13(3):463. doi: 10.3390/genes13030463.
The most often diagnosed malignancy in women worldwide is cancer of the cervix. It is also the most prevalent kind of gynecological cancer in women. This cancer originates in the opening of the cervix and spreads through sexual contact. Even though human papillomavirus (HPV) may not cause cancer immediately, it does develop over time as a result of the virus's lengthy persistence to cause dysplastic changes overtime, particularly in high-risk kinds. The primary objective of this research is to see if miRNAs are dysregulated as a result of treatment resistance in cervical cancer (CC). The aim is to see if these microRNAs may be utilized as biomarkers for detecting chemoresistance in CC, particularly for clinical applications.
The recommended protocol for comprehensive study and meta-analysis (PRISMA-P) standards will be utilized for the analysis and data interpretation. The bibliographic databases will be methodically searched using a combination of search keywords. Based on established inclusion and exclusion criteria, the acquired findings will be reviewed, and data retrieved from the selected scientific papers for systematic review. We will then construct a forest from the pooled Hazard ratio (HR) and 95% C.I. values, data obtained using the random-effects model.
The focus of this study is to identify the function of miRNAs as a chemoresistance regulator and determine if they have the potential scope to be considered as biomarkers for cervical cancer. Through this systematic review and meta-analysis, the goal is to collect, compare, and analyze the data pertaining to the role of miRNAs in cervical cancer, thereby, enabling us to understand the role they play in chemosensitivity.
全球范围内，女性最常被诊断出的恶性肿瘤是宫颈癌。它也是女性最常见的妇科癌症。这种癌症起源于宫颈开口处，通过性接触传播。尽管人乳头瘤病毒（HPV）可能不会立即引发癌症，但随着病毒的长期存在，它会逐渐发展为异常变化，尤其是高危型 HPV。本研究的主要目的是观察宫颈癌（CC）治疗耐药是否导致 miRNA 失调。目的是观察这些 microRNA 是否可以作为 CC 化疗耐药的生物标志物，特别是在临床应用中。
将采用综合研究和荟萃分析（PRISMA-P）标准对分析和数据解释进行推荐。将通过搜索关键字的组合系统地搜索文献数据库。根据既定的纳入和排除标准，对获得的发现进行审查，并从选定的科学论文中检索数据进行系统评价。然后，我们将使用随机效应模型获得的汇总风险比（HR）和 95%置信区间（CI）值构建森林。
本研究的重点是确定 miRNA 作为化疗耐药调节剂的功能，并确定它们是否有可能被考虑作为宫颈癌的生物标志物。通过这项系统评价和荟萃分析，我们的目标是收集、比较和分析 miRNA 在宫颈癌中的作用数据，从而了解它们在化疗敏感性中的作用。
